2-(Methoxymethyl)-5-methylpyrrolidine | 1032050-91-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-(Methoxymethyl)-5-methylpyrrolidine
• CAS: 1032050-91-1
• 化学式: C₇H₁₅NO
• mdl: MFCD19227660
• 分子量: 129.202
• InChiKey: VFGSTDZBFIIDJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(methoxymethyl)pent-4-enylamine 在 C₇₄H₆₅N₂O₂Si₂Y 作用下， 以 氘代苯 为溶剂， 反应 85.0h， 生成 2-(Methoxymethyl)-5-methylpyrrolidine 、 (1S)-1-(methoxymethyl)pent-4-enylamine 、 (1R)-1-(methoxymethyl)pent-4-enylamine
  参考文献：
  名称：

  氨基烯类通过不对称加氢胺的动力学拆分：机理研究

  摘要：

  使用3，3′-双（三芳基甲硅烷基）取代的邻萘二甲酸稀土金属配合物研究了手性氨基烯烃通过加氢胺化反应的动力学拆分。1-芳基氨基戊烯的拆分具有较高的效率和较高的反式-非对映选择性，而1-烷基氨基戊烯的拆分过程则随着脂肪族取代基的空间需求的增加而降低了拆分效率。通过使用对映纯底物和（R）-或（S）-萘甲酸酯催化剂显示，分离效率的差异源于科廷-汉米特预平衡的变化。尽管1-芳基氨基戊烯偏爱匹配的底物-催化剂配合物，但对于1-烷基氨基戊烯偏爱错配的底物-催化剂配合物却降低了分离效率。然而，两种非对映异构底物-催化剂复合物的相对环化率通常在7-10：1的范围内。芳基取代基与双（三芳基甲硅烷基）取代的邻萘二甲酸酯配体的金属中心或芳族体系之间可能存在的吸引性π相互作用可能解释了匹配的底物-催化剂配合物的稳定性提高。顺便说一句，甲氧基甲基（MOM）取代的氨基戊烯3 g由于MOM取代基的螯合性质，它也表现出对匹

  DOI：

  10.1002/chem.200902229

文献信息

• PYRAZOLE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1762568A1

  公开（公告）日：2007-03-14

  A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

  由式(I)表示的化合物： （其中Ar1代表可能具有1到3个取代基的苯基，或者是非取代的5-或6-成员芳香杂环基团；Ar2代表（i）非取代的苯基团，（ii）已被1到3个来自羰胺基、氨基、羟基、低烷氧基和卤原子的群或原子取代的较低烷基基团取代的苯基团，或者（iii）已被1到3个来自低烷基基团、低炔基基团、低烷酰基团、羰胺基、氰基、氨基、羟基、低烷氧基和卤原子的群或原子取代的5-或6-成员含氮芳香杂环基团；X代表由式(II)表示的基团： （其中环结构表示可能具有除了式(II)中显示的氮原子之外，从氮、氧和硫中选择的一个杂原子的4-到7-成员杂环基团，并且可能被1到4个来自低烷基基团、羰胺基、氨基、羟基、低烷氧基、氧基、低烷酰基团、低烷基磺酰基团和卤原子的群或原子取代）），其盐，该化合物或其盐的溶剂化合物，以及药物。
• Pyrazole Derivatives
  申请人：Kanaya Naoaki

  公开号：US20080064682A1

  公开（公告）日：2008-03-13

  A compound represented by formula (I): (wherein Ar 1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar 2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, a sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

  化合物的化学式为(I)：其中Ar1代表一个苯基，它可能有1到3个取代基，或者是一个非取代的5-或6-成员的芳香杂环基；Ar2代表(i)一个非取代的苯基，(ii)一个已经被1到3个来自羰基基团、氨基基团、羟基基团、低级烷氧基团和卤原子的较低烷基取代的苯基，或者(iii)一个已经被1到3个来自较低烷基、较低炔基、较低烷酰基、羰基基团、氰基基团、氨基基团、羟基基团、低级烷氧基团和卤原子的取代的5-或6-成员的含氮芳香杂环基；X代表一个化学式(II)所代表的基团：(其中环结构代表一个4-到7-成员的杂环基，它可能有除了在化学式(II)中显示的氮原子之外的一个来自氮、氧、硫的杂原子，它可能被1到4个来自较低烷基、羰基基团、氨基基团、羟基基团、低级烷氧基团、氧基基团、较低烷酰基、较低烷基磺酰基和卤原子的取代基所取代)，它的盐、该化合物或其盐的溶剂化物，以及药物。
• Pyrazole Derivative
  申请人：Kanaya Naoaki

  公开号：US20070254881A1

  公开（公告）日：2007-11-01

  A compound represented by Formula (I): wherein Ar 1 represents Formula (II): Ar 2 represents a 5- or 6-membered aromatic heterocyclic group which may be substituted; and X represents Formula (III): a salt thereof, or a solvate of the compound or the salt. A potent platelet aggregation suppressant which does not inhibit COX-1 and COX-2 is provided.

  提供了一种化合物，其化学式表示为（I）：其中Ar1表示化学式（II）：Ar2表示5或6成员的芳香杂环基团，可以被取代；X表示化学式（III）：其盐或化合物或盐的溶剂。提供了一种有效的血小板聚集抑制剂，它不抑制COX-1和COX-2。
• 1,5-Diheterocycle-1H-Triazole Derivative
  申请人：Kanaya Naoaki

  公开号：US20080125409A1

  公开（公告）日：2008-05-29

  The present invention relates to a compound represented by Formula (I): wherein Ar 1 , Ar 2 , R 1 and R 2 each represent a substituent, a salt thereof, or a solvate of the compound or the salt, and to a medicine containing the same. According to the present invention, a potent platelet aggregation suppressant which does not inhibit COX-1 and COX-2 is provided.

  本发明涉及一种由式（I）表示的化合物：其中Ar1，Ar2，R1和R2各代表取代基，其盐或该化合物或该盐的溶剂，以及包含该化合物的药物。根据本发明，提供了一种不抑制COX-1和COX-2的强效血小板聚集抑制剂。
• PYRAZOLE DERIVATIVE
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1785418A1

  公开（公告）日：2007-05-16

  A compound represented by Formula (I): wherein Ar1 represents Formula (II): Ar2 represents a 5- or 6-membered aromatic heterocyclic group which may be substituted; and X represents Formula (III): a salt thereof, or a solvate of the compound or the salt. A potent platelet aggregation suppressant which does not inhibit COX-1 and COX-2 is provided.

  由式 (I) 代表的化合物： 其中 Ar1 代表式 (II)： Ar2 代表可被取代的 5 或 6 元芳香杂环基团；以及 X 代表式（III）： 其盐，或该化合物或其盐的溶液。 本发明提供了一种不抑制 COX-1 和 COX-2 的强效血小板聚集抑制剂。